Hideki Kawanishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hideki Kawanishi has a total of 503 co-authors. Here are the top co-authors by number of shared publications:
Misaki Moriishi
Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
28 shared publicationsShinichiro Tsuchiya
Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan
17 shared publications- Naoko Takahashi
Department of Internal Medicine; Omachi Tsuchiya Clinic; Hiroshima Japan
8 shared publications Hiroshi Watanabe
Akane Foundation, Tsuchiya General Hospital, Hiroshima, Japan
7 shared publicationsTaro Tsuchiya
7 shared publicationsRyo Shinhara
6 shared publications
Latest Publications
- 10 December 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (10) , 1836-1846
Sex-Specific Outcomes in the Peritoneal Dialysis Outcomes and Practice Patterns Study
Sex differences may influence peritoneal dialysis (PD) outcomes for individuals with kidney failure and remain poorly understood. Understanding these differences is important in optimizing dialysis care and addressing disparities in treatment outcomes. We sought to explore association of sex with PD outcomes. Data from the international PD Outcomes and Practice Patterns Study across eight countries were used to examine sex differences in outcomes, including mortality, transfer to hemodialysis, the composite of both, peritonitis risks, and kidney transplantation. Cause-specific Cox regression models were used to assess the association between sex and each clinical outcome, adjusting for region, comorbidities, demographic, and treatment characteristics. Of 26,292 included individuals on PD, 43% were female, ranging from 34% in Japan to 51% in Thailand. Women (compared with men) had lower mortality (rate per 100 patient-years [PY100], 10.9 versus 11.3; adjusted hazard ratio [aHR] of mortality, 0.92 [95% confidence intervals (CIs), 0.86 to 0.99]), transfer to hemodialysis (PY100, 16.3 versus 17.9; aHR, 0.87 [95% CI, 0.83 to 0.92]), the composite of both (PY100, 27.2 versus 29.0; aHR, 0.89 [95% CI, 0.85 to 0.93]), and time to first observed peritonitis (PY100, 17.5 versus 18.7; aHR, 0.90 [95% CI, 0.84 to 0.95]), while transplant hazards were similar (PY100, 4.0 versus 4.0; aHR, 0.97 [95% CI, 0.87 to 1.08]). In subgroup and additional analyses, sex differences in outcomes were particularly apparent in South Korea, with a median time on PD of 6.4 years for women and 4.9 years for men, with South Korea women having lower hemodialysis transfer and transplant rates. Across all countries, diabetes substantially attenuated the lower risks of death and hemodialysis transfer in women. Women had significantly lower risks of gram-positive peritonitis (aHR, 0.73 [95% CI, 0.65 to 0.82]). Compared with men, women receiving PD have lower likelihoods of mortality, hemodialysis transfer, and peritonitis. Better understanding of these findings will help inform sex-specific strategies for managing PD while enhancing personalized care approaches in this patient population.
- 10 December 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (10) , 1836-1846
Sex-Specific Outcomes in the Peritoneal Dialysis Outcomes and Practice Patterns Study
Sex differences may influence peritoneal dialysis (PD) outcomes for individuals with kidney failure and remain poorly understood. Understanding these differences is important in optimizing dialysis care and addressing disparities in treatment outcomes. We sought to explore association of sex with PD outcomes. Data from the international PD Outcomes and Practice Patterns Study across eight countries were used to examine sex differences in outcomes, including mortality, transfer to hemodialysis, the composite of both, peritonitis risks, and kidney transplantation. Cause-specific Cox regression models were used to assess the association between sex and each clinical outcome, adjusting for region, comorbidities, demographic, and treatment characteristics. Of 26,292 included individuals on PD, 43% were female, ranging from 34% in Japan to 51% in Thailand. Women (compared with men) had lower mortality (rate per 100 patient-years [PY100], 10.9 versus 11.3; adjusted hazard ratio [aHR] of mortality, 0.92 [95% confidence intervals (CIs), 0.86 to 0.99]), transfer to hemodialysis (PY100, 16.3 versus 17.9; aHR, 0.87 [95% CI, 0.83 to 0.92]), the composite of both (PY100, 27.2 versus 29.0; aHR, 0.89 [95% CI, 0.85 to 0.93]), and time to first observed peritonitis (PY100, 17.5 versus 18.7; aHR, 0.90 [95% CI, 0.84 to 0.95]), while transplant hazards were similar (PY100, 4.0 versus 4.0; aHR, 0.97 [95% CI, 0.87 to 1.08]). In subgroup and additional analyses, sex differences in outcomes were particularly apparent in South Korea, with a median time on PD of 6.4 years for women and 4.9 years for men, with South Korea women having lower hemodialysis transfer and transplant rates. Across all countries, diabetes substantially attenuated the lower risks of death and hemodialysis transfer in women. Women had significantly lower risks of gram-positive peritonitis (aHR, 0.73 [95% CI, 0.65 to 0.82]). Compared with men, women receiving PD have lower likelihoods of mortality, hemodialysis transfer, and peritonitis. Better understanding of these findings will help inform sex-specific strategies for managing PD while enhancing personalized care approaches in this patient population.
- 11 October 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (12) , 1622-1634
Prevalence and Outcomes of Chronic Kidney Disease-Associated Pruritus
Key Points: CKD-associated pruritus is highly prevalent among peritoneal dialysis patients. Pruritus is associated with reduced health-related quality of life, and the composite of mortality and transfer to hemodialysis for peritoneal dialysis patients. Efforts to better identify and manage pruritus in this population are needed. Background: Pruritus is common in hemodialysis patients. Less is known about the prevalence and outcomes of pruritus among patients receiving peritoneal dialysis (PD). Herein, we describe the prevalence of pruritus and its associations with patient-reported outcomes (PROs) and mortality/transfer to hemodialysis. Methods: We analyzed a multicenter, international cohort of PD patients enrolled in the PD Outcomes and Practice Patterns Study from 2014 to 2022. Pruritus was assessed at entry into the PD Outcomes and Practice Patterns Study with a single-question Likert Scale capturing the extent to which patients were bothered by itch ranging from 1: not at all to 5: extremely . The kidney disease quality of life-36 and the Center for Epidemiological Studies Depression Scale assessed various PROs. Moderate-to-extreme pruritus was defined as a Likert scale score ≥3. The associations of pruritus with PROs were assessed using linear/logistic regression where appropriate. Death or hemodialysis transfer was assessed using multivariable Cox regression models. Results: Overall, 5535 patients from eight countries were included; 43% had moderate-to-extreme pruritus which was the highest in Thailand (50%) and the lowest in the United States (33%). The adjusted odds ratios of moderate-to-extreme pruritus were higher for diabetes, low albumin, and elevated phosphorus but lower for residual urine volume (adjusted odds ratio, 0.98 per 200 ml increase in 24-hour urine volume; 95% confidence interval, 0.96 to 1.00; P = 0.05). Patients with extreme pruritus had the lowest mental and physical health component scores and a higher burden of other PROs including restless legs and disturbed sleep. Overall, 921 patients died and 1150 were transferred to hemodialysis. Patients with moderate-to-extreme pruritus were at higher adjusted risk for death or hemodialysis transfer (adjusted hazard ratio, 1.12; 95% confidence interval, 1.02 to 1.23; P = 0.02) with similar point estimates for each subcomponent of the composite outcome. Conclusions: Pruritus is highly prevalent in PD and associated with poor health outcomes. Efforts to better identify and manage pruritus should be considered in this population.
- 11 October 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (12) , 1622-1634
Prevalence and Outcomes of Chronic Kidney Disease-Associated Pruritus
Key Points: CKD-associated pruritus is highly prevalent among peritoneal dialysis patients. Pruritus is associated with reduced health-related quality of life, and the composite of mortality and transfer to hemodialysis for peritoneal dialysis patients. Efforts to better identify and manage pruritus in this population are needed. Background: Pruritus is common in hemodialysis patients. Less is known about the prevalence and outcomes of pruritus among patients receiving peritoneal dialysis (PD). Herein, we describe the prevalence of pruritus and its associations with patient-reported outcomes (PROs) and mortality/transfer to hemodialysis. Methods: We analyzed a multicenter, international cohort of PD patients enrolled in the PD Outcomes and Practice Patterns Study from 2014 to 2022. Pruritus was assessed at entry into the PD Outcomes and Practice Patterns Study with a single-question Likert Scale capturing the extent to which patients were bothered by itch ranging from 1: not at all to 5: extremely . The kidney disease quality of life-36 and the Center for Epidemiological Studies Depression Scale assessed various PROs. Moderate-to-extreme pruritus was defined as a Likert scale score ≥3. The associations of pruritus with PROs were assessed using linear/logistic regression where appropriate. Death or hemodialysis transfer was assessed using multivariable Cox regression models. Results: Overall, 5535 patients from eight countries were included; 43% had moderate-to-extreme pruritus which was the highest in Thailand (50%) and the lowest in the United States (33%). The adjusted odds ratios of moderate-to-extreme pruritus were higher for diabetes, low albumin, and elevated phosphorus but lower for residual urine volume (adjusted odds ratio, 0.98 per 200 ml increase in 24-hour urine volume; 95% confidence interval, 0.96 to 1.00; P = 0.05). Patients with extreme pruritus had the lowest mental and physical health component scores and a higher burden of other PROs including restless legs and disturbed sleep. Overall, 921 patients died and 1150 were transferred to hemodialysis. Patients with moderate-to-extreme pruritus were at higher adjusted risk for death or hemodialysis transfer (adjusted hazard ratio, 1.12; 95% confidence interval, 1.02 to 1.23; P = 0.02) with similar point estimates for each subcomponent of the composite outcome. Conclusions: Pruritus is highly prevalent in PD and associated with poor health outcomes. Efforts to better identify and manage pruritus should be considered in this population.
- Open Access
- 23 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (3) , 647
Middle Molecular Uremic Toxin and Blood Purification Therapy
The purpose of blood purification therapy is to remove uremic toxins, and middle molecules (MMs) are a specific target. An MM is defined as a solute that passes through the glomerulus with a molecular weight in the range of 0.5–58 kDa, and new classifications of “small-middle 0.5–15 kDa,” “medium-middle 15–25 kDa,” and “large-middle 25–58 kDa” were proposed. In Japan, the removal of α1-microglobulin (αMG) in the large-middle range has been the focus, but a new theory of removal has been developed, emphasizing the antioxidant effect of αMG as a physiological function. Clinical proof of this mechanism will lead to further development of blood purification therapies.
- 23 January 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (3) , 647
Open AccessMiddle Molecular Uremic Toxin and Blood Purification Therapy
The purpose of blood purification therapy is to remove uremic toxins, and middle molecules (MMs) are a specific target. An MM is defined as a solute that passes through the glomerulus with a molecular weight in the range of 0.5–58 kDa, and new classifications of “small-middle 0.5–15 kDa,” “medium-middle 15–25 kDa,” and “large-middle 25–58 kDa” were proposed. In Japan, the removal of α1-microglobulin (αMG) in the large-middle range has been the focus, but a new theory of removal has been developed, emphasizing the antioxidant effect of αMG as a physiological function. Clinical proof of this mechanism will lead to further development of blood purification therapies.
- Open Access
- 15 September 2022
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 8 (1) , 1-7
Historical overview and current practice of peritoneal dialysis in Japan
In the early days of peritoneal dialysis (PD) therapy, its limited duration and peritoneal deterioration were argued to be its disadvantages. Biocompatible solutions and hybrid therapy have been used in Japan to overcome these issues, which resulted in a decrease in encapsulating peritoneal sclerosis (EPS) incidence and an extension of PD continuation; these results have been disseminated worldwide. Peritoneal dialysis outcomes and practice patterns study (PDOPPS), a prospective observational study, has begun to confirm the outcomes of PD therapy, and sufficient evidence has been published, which has influenced the preparation of PD guidelines. Current thinking about PD emphasizes the need to maintain quality of life and life goals as care goals for patients and to provide high-quality care. However, we must conduct basic research on the prevention of peritoneal deterioration.
- 15 September 2022
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 8 (1) , 1-7
Open AccessHistorical overview and current practice of peritoneal dialysis in Japan
In the early days of peritoneal dialysis (PD) therapy, its limited duration and peritoneal deterioration were argued to be its disadvantages. Biocompatible solutions and hybrid therapy have been used in Japan to overcome these issues, which resulted in a decrease in encapsulating peritoneal sclerosis (EPS) incidence and an extension of PD continuation; these results have been disseminated worldwide. Peritoneal dialysis outcomes and practice patterns study (PDOPPS), a prospective observational study, has begun to confirm the outcomes of PD therapy, and sufficient evidence has been published, which has influenced the preparation of PD guidelines. Current thinking about PD emphasizes the need to maintain quality of life and life goals as care goals for patients and to provide high-quality care. However, we must conduct basic research on the prevention of peritoneal deterioration.
- Open Access
- 15 June 2022
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 8 (1) , 1
Retraction Note: Impact of the third wave of the COVID-19 pandemic and interventions to contain the virus on society and patients with kidney disease in Cambodia
[This retracts the article DOI: 10.1186/s41100-021-00372-6.].
- 15 June 2022
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 8 (1) , 1
Open AccessRetraction Note: Impact of the third wave of the COVID-19 pandemic and interventions to contain the virus on society and patients with kidney disease in Cambodia
[This retracts the article DOI: 10.1186/s41100-021-00372-6.].
- 1 June 2022
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (6) , 861-871
Variation in Peritoneal Dialysis Time on Therapy by Country
Background and objectives: Quantifying contemporary peritoneal dialysis time on therapy is important for patients and providers. We describe time on peritoneal dialysis in the context of outcomes of hemodialysis transfer, death, and kidney transplantation on the basis of the multinational, observational Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS) from 2014 to 2017. Design, setting, participants, & measurements: Among 218 randomly selected peritoneal dialysis facilities (7121 patients) in the PDOPPS from Australia/New Zealand, Canada, Japan, Thailand, the United Kingdom, and the United States, we calculated the cumulative incidence from peritoneal dialysis start to hemodialysis transfer, death, or kidney transplantation over 5 years and adjusted hazard ratios for patient and facility factors associated with death and hemodialysis transfer. Results: Median time on peritoneal dialysis ranged from 1.7 (interquartile range, 0.8–2.9; the United Kingdom) to 3.2 (interquartile range, 1.5–6.0; Japan) years and was longer with lower kidney transplantation rates (range: 32% [the United Kingdom] to 2% [Japan and Thailand] over 3 years). Adjusted hemodialysis transfer risk was lowest in Thailand, but death risk was higher in Thailand and the United States compared with most countries. Infection was the leading cause of hemodialysis transfer, with higher hemodialysis transfer risks seen in patients having psychiatric disorder history or elevated body mass index. The proportion of patients with total weekly Kt/V ≥1.7 at a facility was not associated with death or hemodialysis transfer. Conclusions: Countries in the PDOPPS with higher rates of kidney transplantation tended to have shorter median times on peritoneal dialysis. Identification of infection as a leading cause of hemodialysis transfer and patient and facility factors associated with the risk of hemodialysis transfer can facilitate interventions to reduce these events. Podcast: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2022_05_31_CJN16341221.mp3
- 1 June 2022
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (6) , 861-871
Variation in Peritoneal Dialysis Time on Therapy by Country
Background and objectives: Quantifying contemporary peritoneal dialysis time on therapy is important for patients and providers. We describe time on peritoneal dialysis in the context of outcomes of hemodialysis transfer, death, and kidney transplantation on the basis of the multinational, observational Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS) from 2014 to 2017. Design, setting, participants, & measurements: Among 218 randomly selected peritoneal dialysis facilities (7121 patients) in the PDOPPS from Australia/New Zealand, Canada, Japan, Thailand, the United Kingdom, and the United States, we calculated the cumulative incidence from peritoneal dialysis start to hemodialysis transfer, death, or kidney transplantation over 5 years and adjusted hazard ratios for patient and facility factors associated with death and hemodialysis transfer. Results: Median time on peritoneal dialysis ranged from 1.7 (interquartile range, 0.8–2.9; the United Kingdom) to 3.2 (interquartile range, 1.5–6.0; Japan) years and was longer with lower kidney transplantation rates (range: 32% [the United Kingdom] to 2% [Japan and Thailand] over 3 years). Adjusted hemodialysis transfer risk was lowest in Thailand, but death risk was higher in Thailand and the United States compared with most countries. Infection was the leading cause of hemodialysis transfer, with higher hemodialysis transfer risks seen in patients having psychiatric disorder history or elevated body mass index. The proportion of patients with total weekly Kt/V ≥1.7 at a facility was not associated with death or hemodialysis transfer. Conclusions: Countries in the PDOPPS with higher rates of kidney transplantation tended to have shorter median times on peritoneal dialysis. Identification of infection as a leading cause of hemodialysis transfer and patient and facility factors associated with the risk of hemodialysis transfer can facilitate interventions to reduce these events. Podcast: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2022_05_31_CJN16341221.mp3
- 1 March 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (5) , 872-882
International Icodextrin Use and Association with Peritoneal Membrane Function, Fluid Removal, Patient and Technique Survival
Key Points: There are important national and center differences in the prescription of icodextrin, with the United States a clear outlier; across all countries, icodextrin was more likely to be used if membrane function tests indicated reduced ultrafiltration capacity to glucose. This large, international observational study was unable to show patient or hemodialysis transfer advantages to icodextrin use. Where use of icodextrin was low, this was compensated for by much greater use of high glucose and overall higher ultrafiltration volumes at each level of urine volume; this practice may confound associations between icodextrin and survival outcomes. Background: Icodextrin has been shown in randomized controlled trials to benefit fluid management in peritoneal dialysis (PD). We describe international icodextrin prescription practices and their relationship to clinical outcomes. Methods: We analyzed data from the prospective, international PDOPPS, from Australia/New Zealand, Canada, Japan, the United Kingdom, and the United States. Membrane function and 24-hour ultrafiltration according to icodextrin and glucose prescription was determined at baseline. Using an instrumental variable approach, Cox regression, stratified by country, was used to determine any association of icodextrin use to death and permanent transfer to hemodialysis (HDT), adjusted for demographics, comorbidities, serum albumin, urine volume, transplant waitlist status, PD modality, center size, and study phase. Results: Icodextrin was prescribed in 1986 (35%) of 5617 patients, >43% of patients in all countries, except in the United States, where it was only used in 17% and associated with a far greater use of hypertonic glucose. Patients on icodextrin had more coronary artery disease and diabetes, longer dialysis vintage, lower residual kidney function, faster peritoneal solute transfer rates, and lower ultrafiltration capacity. Prescriptions with or without icodextrin achieved equivalent ultrafiltration (median 750 ml/d [interquartile range 300–1345 ml/d] versus 765 ml/d [251–1345 ml/d]). Icodextrin use was not associated with mortality (HR=1.03; 95% CI, 0.72 to 1.48) or HDT (HR 1.2; 95% CI, 0.92 to 1.57). Conclusions: There are large national and center differences in icodextrin prescription, with the United States using significantly less. Icodextrin was associated with hypertonic glucose avoidance but equivalent ultrafiltration, which may affect any potential survival advantage or HDT.
- 1 March 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (5) , 872-882
International Icodextrin Use and Association with Peritoneal Membrane Function, Fluid Removal, Patient and Technique Survival
Key Points: There are important national and center differences in the prescription of icodextrin, with the United States a clear outlier; across all countries, icodextrin was more likely to be used if membrane function tests indicated reduced ultrafiltration capacity to glucose. This large, international observational study was unable to show patient or hemodialysis transfer advantages to icodextrin use. Where use of icodextrin was low, this was compensated for by much greater use of high glucose and overall higher ultrafiltration volumes at each level of urine volume; this practice may confound associations between icodextrin and survival outcomes. Background: Icodextrin has been shown in randomized controlled trials to benefit fluid management in peritoneal dialysis (PD). We describe international icodextrin prescription practices and their relationship to clinical outcomes. Methods: We analyzed data from the prospective, international PDOPPS, from Australia/New Zealand, Canada, Japan, the United Kingdom, and the United States. Membrane function and 24-hour ultrafiltration according to icodextrin and glucose prescription was determined at baseline. Using an instrumental variable approach, Cox regression, stratified by country, was used to determine any association of icodextrin use to death and permanent transfer to hemodialysis (HDT), adjusted for demographics, comorbidities, serum albumin, urine volume, transplant waitlist status, PD modality, center size, and study phase. Results: Icodextrin was prescribed in 1986 (35%) of 5617 patients, >43% of patients in all countries, except in the United States, where it was only used in 17% and associated with a far greater use of hypertonic glucose. Patients on icodextrin had more coronary artery disease and diabetes, longer dialysis vintage, lower residual kidney function, faster peritoneal solute transfer rates, and lower ultrafiltration capacity. Prescriptions with or without icodextrin achieved equivalent ultrafiltration (median 750 ml/d [interquartile range 300–1345 ml/d] versus 765 ml/d [251–1345 ml/d]). Icodextrin use was not associated with mortality (HR=1.03; 95% CI, 0.72 to 1.48) or HDT (HR 1.2; 95% CI, 0.92 to 1.57). Conclusions: There are large national and center differences in icodextrin prescription, with the United States using significantly less. Icodextrin was associated with hypertonic glucose avoidance but equivalent ultrafiltration, which may affect any potential survival advantage or HDT.
- Open Access
- 2 October 2021
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 7 (1) , 1-10
Development of online hemodiafiltration in Japan
Evidence concerning online hemodiafiltration (ol-HDF) includes increased uremic toxin removal, prevention of dialysis-related hypotension, improved survival, and recovery of dialysis-related uncertain symptoms. In particular, evidence has been shown regarding prevention of dialysis hypotension and improvement of survival, but the mechanism of its manifestation is still unclear and its effects themselves are questionable. In Japan, pre dilution ol-HDF is mainly performed, and improvement in survival rate has been shown on the condition of convection volume is 40 L/session or more. In particular, the removal of α1-microglubulin (αMG), which is a medium-middle solute, is targeted. The antioxidant action (Heme Scavenger) of αMG, is presumed, but in dialysis patients, the majority in serum are deteriorated (oxidized) αMG. It has been pointed out that removing the deteriorated αMG by ol-HDF may produce new αMG from the liver and lead to recovery of the original antioxidant effect. However, clinical evidence of this mechanism is desired. Obtaining evidence for the indicated αMG removal activity of ol-HDF will lead to advancement in HDF.
- 2 October 2021
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 7 (1) , 1-10
Open AccessDevelopment of online hemodiafiltration in Japan
Evidence concerning online hemodiafiltration (ol-HDF) includes increased uremic toxin removal, prevention of dialysis-related hypotension, improved survival, and recovery of dialysis-related uncertain symptoms. In particular, evidence has been shown regarding prevention of dialysis hypotension and improvement of survival, but the mechanism of its manifestation is still unclear and its effects themselves are questionable. In Japan, pre dilution ol-HDF is mainly performed, and improvement in survival rate has been shown on the condition of convection volume is 40 L/session or more. In particular, the removal of α1-microglubulin (αMG), which is a medium-middle solute, is targeted. The antioxidant action (Heme Scavenger) of αMG, is presumed, but in dialysis patients, the majority in serum are deteriorated (oxidized) αMG. It has been pointed out that removing the deteriorated αMG by ol-HDF may produce new αMG from the liver and lead to recovery of the original antioxidant effect. However, clinical evidence of this mechanism is desired. Obtaining evidence for the indicated αMG removal activity of ol-HDF will lead to advancement in HDF.
- Open Access
- 1 September 2019
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 11, 579-590
Health economic evaluation of peritoneal dialysis based on cost-effectiveness in Japan: a preliminary study
Background: In Japan, the medical expenditures associated with dialysis have garnered considerable interest; however, a cost-effectiveness evaluation of peritoneal dialysis (PD) is yet to be evaluated. In particular, the health economics of the “PD first” concept, which can be advantageous for clinical practice and healthcare systems, must be evaluated. Methods: This multicenter study investigated the cost-effectiveness of PD. The major effectiveness indicator was quality-adjusted life year (QALY), with a preference-based utility value based on renal function, and the cost indicator was the amount billed for a medical service at each medical institution for qualifying illnesses. In comparison with hemodialysis (HD), a baseline analysis of PD therapy was conducted using a cost-utility analysis (CUA). Continuous ambulatory PD (CAPD) and automated PD (APD) were compared based on the incremental cost-utility ratio (ICUR) and propensity score (PS) with a limited number of cases. Results: The mean duration since the start of PD was 35.0±14.4 months. The overall CUA for PD (179 patients) was USD 55,019/QALY, which was more cost effective (USD/monthly utility) compared with that for HD for 12–24 months (4,367 vs. 4,852; ppConclusion: The cost-effectiveness of PD was potentially good in the elderly and in patients on dialysis for <24 months. Therefore, the prevalence of PD may influence the public health insurance system, particularly when applying the “PD first” concept.
- 1 September 2019
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 11, 579-590
Open AccessHealth economic evaluation of peritoneal dialysis based on cost-effectiveness in Japan: a preliminary study
Background: In Japan, the medical expenditures associated with dialysis have garnered considerable interest; however, a cost-effectiveness evaluation of peritoneal dialysis (PD) is yet to be evaluated. In particular, the health economics of the “PD first” concept, which can be advantageous for clinical practice and healthcare systems, must be evaluated. Methods: This multicenter study investigated the cost-effectiveness of PD. The major effectiveness indicator was quality-adjusted life year (QALY), with a preference-based utility value based on renal function, and the cost indicator was the amount billed for a medical service at each medical institution for qualifying illnesses. In comparison with hemodialysis (HD), a baseline analysis of PD therapy was conducted using a cost-utility analysis (CUA). Continuous ambulatory PD (CAPD) and automated PD (APD) were compared based on the incremental cost-utility ratio (ICUR) and propensity score (PS) with a limited number of cases. Results: The mean duration since the start of PD was 35.0±14.4 months. The overall CUA for PD (179 patients) was USD 55,019/QALY, which was more cost effective (USD/monthly utility) compared with that for HD for 12–24 months (4,367 vs. 4,852; ppConclusion: The cost-effectiveness of PD was potentially good in the elderly and in patients on dialysis for <24 months. Therefore, the prevalence of PD may influence the public health insurance system, particularly when applying the “PD first” concept.
- Open Access
- 12 April 2018
- Published by S. Karger AG in Blood Purification
- Vol. 46 (1) , 3-6
Is There Enough Evidence to Prove That Hemodiafiltration Is Superior?
The evidence concerning online hemodiafiltration (HDF) includes the following: (1) the increase of removal of uremic toxin, (2) the prevention of dialysis rerated hypotension, (3) the recovery of survival, and (4) the recovery of dialysis related uncertain symptoms. Although clinical evidence has been noted, the hypothesis of the efficacy of HDF are still indefinite and require further precise research.
- 12 April 2018
- Published by S. Karger AG in Blood Purification
- Vol. 46 (1) , 3-6
Open AccessIs There Enough Evidence to Prove That Hemodiafiltration Is Superior?
The evidence concerning online hemodiafiltration (HDF) includes the following: (1) the increase of removal of uremic toxin, (2) the prevention of dialysis rerated hypotension, (3) the recovery of survival, and (4) the recovery of dialysis related uncertain symptoms. Although clinical evidence has been noted, the hypothesis of the efficacy of HDF are still indefinite and require further precise research.